TS01.02 Novel Anti–CTLA-4 Antibody Quavonlimab Plus Pembrolizumab as First-Line Therapy for NSCLC: Extended Follow-up From a Phase 1 Study

B.C. Cho,R. Perets, D.W. Rasco, M.-J. Ahn, D.R. Spigel, K. Yoh,D.-W. Kim,M. Gutierrez, D.H. Lee,A. Nagrial,M. Satouchi, D. Kotasek,C. Maurice-Dror,J. Niu, M. Rajasagi, S. Siddiqi,Xiaoyun (Nicole) Li,J. Cyrus, R.A. Altura,J. Bar

Journal of Thoracic Oncology（2021）

引用 0|浏览8

暂无评分

关键词

Pembrolizumab,Antibody,Oncology,Medicine,Anti ctla 4,First line therapy,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要